Literature DB >> 1830582

Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor.

E V Granowitz1, B D Clark, J Mancilla, C A Dinarello.   

Abstract

The interleukin-1 receptor antagonist (IL-1ra) inhibits the binding of interleukin-1 (IL-1) to T-cell lines possessing the type I IL-1 receptor; evidence has been published (Carter, D. B., Deibel, M. R. J., Dunn, C. J., Tomich, C. S., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., Harris, P. K. W., Yem, A. W., Waszak, G. A., Chosay, J. G., Sieu, L. C., Hardee, M. M., Zurcher-Neely, H. A., Reardon, I. M., Heinrickson, R. L., Truesdell, S. E., Shelly, J. A., Eessalu, T. E., Taylor, B. M., and Tracey, D. E. (1990) Nature 344, 633-638; Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., and Thompson, R. C. (1990) Nature 343, 336-340) that IL-Ira does not bind to the type II IL-1 receptor (IL-1RtII). In this study we examined the ability of human recombinant IL-1ra to block the binding of IL-1 to the IL-1RtII on human polymorphonuclear leukocytes (PMN) and Raji human B-lymphoma cells. The binding of 125I-IL-1 beta to PMN was competively inhibited by IL-1ra. IL-1 beta was more potent in inhibiting the binding of 125I-IL-1 beta than IL-1ra. Incubating PMN with 125I-IL-1ra in the presence of increasing concentrations of IL-1 beta or IL-1ra showed that IL-1 beta was an approximately 40-fold more potent inhibitor of binding of 125I-IL-1ra than unlabeled IL-1ra. The IL-1ra was approximately 500-fold less potent in inhibiting the binding of 125I-IL-1 alpha than IL-1 alpha. IL-1ra was also able to competitively inhibit binding of 125I-IL-1 beta to Raji cells. PMN or Raji cells were also incubated with 125I-IL-1 in the absence or presence of IL-1 or IL-1ra. After cross-linking of IL-1 to cells followed by specific immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a band at 85 kDa corresponding to the 68-kDa IL-1RtII. However, in the presence of an excess of either unlabeled IL-1 or IL-1ra, the 85-kDa IL-1.IL-1RtII complex was not present. These findings demonstrate that the IL-1ra recognizes and blocks IL-1 binding to the IL-1RtII.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830582

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Effect of the cytokine levels in serum on osteosarcoma.

Authors:  Hong Xiao; Ling Chen; Gang Luo; Haihang Son; James H Prectoni; Wenjie Zheng
Journal:  Tumour Biol       Date:  2013-09-03

Review 3.  Immune response to stem cells and strategies to induce tolerance.

Authors:  Puspa Batten; Nadia A Rosenthal; Magdi H Yacoub
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

4.  scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy.

Authors:  L R Goodrich; J C Grieger; J N Phillips; N Khan; S J Gray; C W McIlwraith; R J Samulski
Journal:  Gene Ther       Date:  2015-04-23       Impact factor: 5.250

5.  Interleukin-1 beta increases airway epithelial cell mitogenesis partly by stimulating endothelin-1 production.

Authors:  C G Murlas; A C Sharma; A Gulati; F Najmabadi
Journal:  Lung       Date:  1997       Impact factor: 2.584

6.  Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis.

Authors:  Panagiotis Tsirigotis; Spiros Chondropoulos; Konstantinos Gkirkas; Josef Meletiadis; Ioanna Dimopoulou
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

7.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

9.  Genetic Variation in Toll-Interacting Protein Is Associated With Leprosy Susceptibility and Cutaneous Expression of Interleukin 1 Receptor Antagonist.

Authors:  Javeed A Shah; William R Berrington; James C Vary; Richard D Wells; Glenna J Peterson; Chhatra B Kunwar; Saraswoti Khadge; Deanna A Hagge; Thomas R Hawn
Journal:  J Infect Dis       Date:  2015-11-26       Impact factor: 5.226

10.  Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats.

Authors:  U Zumsteg; J I Reimers; F Pociot; L Mørch; S Helqvist; M Brendel; R Alejandro; T Mandrup-Poulsen; C A Dinarello; J Nerup
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.